Your browser doesn't support javascript.
loading
Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
Gerhauser, Clarissa; Favero, Francesco; Risch, Thomas; Simon, Ronald; Feuerbach, Lars; Assenov, Yassen; Heckmann, Doreen; Sidiropoulos, Nikos; Waszak, Sebastian M; Hübschmann, Daniel; Urbanucci, Alfonso; Girma, Etsehiwot G; Kuryshev, Vladimir; Klimczak, Leszek J; Saini, Natalie; Stütz, Adrian M; Weichenhan, Dieter; Böttcher, Lisa-Marie; Toth, Reka; Hendriksen, Josephine D; Koop, Christina; Lutsik, Pavlo; Matzk, Sören; Warnatz, Hans-Jörg; Amstislavskiy, Vyacheslav; Feuerstein, Clarissa; Raeder, Benjamin; Bogatyrova, Olga; Schmitz, Eva-Maria; Hube-Magg, Claudia; Kluth, Martina; Huland, Hartwig; Graefen, Markus; Lawerenz, Chris; Henry, Gervaise H; Yamaguchi, Takafumi N; Malewska, Alicia; Meiners, Jan; Schilling, Daniela; Reisinger, Eva; Eils, Roland; Schlesner, Matthias; Strand, Douglas W; Bristow, Robert G; Boutros, Paul C; von Kalle, Christof; Gordenin, Dmitry; Sültmann, Holger; Brors, Benedikt; Sauter, Guido.
Afiliação
  • Gerhauser C; Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Favero F; Finsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark.
  • Risch T; Max Planck Institute for Molecular Genetics, Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Ihnestrasse 63-73, 14195 Berlin, Germany.
  • Simon R; Department of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Feuerbach L; Division Applied Bioinformatics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
  • Assenov Y; Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Heckmann D; Division of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
  • Sidiropoulos N; Finsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark.
  • Waszak SM; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany.
  • Hübschmann D; Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Department for Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg 69120, Germany; Department of Pediatric
  • Urbanucci A; Centre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, Forskningsparken, University of Oslo, 0316 Oslo, Norway; Institute for Cancer Genetics and Informatics, Oslo University Hospital, 0316 Oslo, Norway; Department of Core Facilities, Institute for Cancer Res
  • Girma EG; Finsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark.
  • Kuryshev V; Division of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
  • Klimczak LJ; Integrative Bioinformatics Support Group, National Institute of Environmental Health Sciences, Durham, 27709 NC, USA.
  • Saini N; Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, Durham, 27709 NC, USA.
  • Stütz AM; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany.
  • Weichenhan D; Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Böttcher LM; Department of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Toth R; Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Hendriksen JD; Finsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark.
  • Koop C; Department of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Lutsik P; Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Matzk S; Max Planck Institute for Molecular Genetics, Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Ihnestrasse 63-73, 14195 Berlin, Germany.
  • Warnatz HJ; Max Planck Institute for Molecular Genetics, Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Ihnestrasse 63-73, 14195 Berlin, Germany.
  • Amstislavskiy V; Max Planck Institute for Molecular Genetics, Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Ihnestrasse 63-73, 14195 Berlin, Germany.
  • Feuerstein C; Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.
  • Raeder B; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany.
  • Bogatyrova O; Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Schmitz EM; PROGETHER Prostate Cancer Network, 0316 Oslo, Norway.
  • Hube-Magg C; Department of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Kluth M; Department of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Huland H; Martini-Clinic Prostate Cancer Center at the University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
  • Graefen M; Martini-Clinic Prostate Cancer Center at the University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
  • Lawerenz C; Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Henry GH; Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390-9110, USA.
  • Yamaguchi TN; Informatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
  • Malewska A; Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390-9110, USA.
  • Meiners J; Department of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Schilling D; Division of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; NCT Trial Center, National Center for Tumor Diseases and German Cancer Research Center, 69120 Heidelberg, Germany.
  • Reisinger E; Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Eils R; Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Department for Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg 69120, Germany.
  • Schlesner M; Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Bioinformatics and Omics Data Analytics (B240), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
  • Strand DW; Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390-9110, USA.
  • Bristow RG; Manchester Cancer Research Centre, University of Manchester, 555 Wilmslow Road, Manchester, UK.
  • Boutros PC; Ontario Institute for Cancer Research, Toronto, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Canada.
  • von Kalle C; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany; Division of Translational Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Gordenin D; Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, Durham, 27709 NC, USA.
  • Sültmann H; Division of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
  • Brors B; Division Applied Bioinformatics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
  • Sauter G; Department of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Cancer Cell ; 34(6): 996-1011.e8, 2018 12 10.
Article em En | MEDLINE | ID: mdl-30537516
ABSTRACT
Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Our integrative analysis identified four molecular subgroups, including a particularly aggressive subgroup with recurrent duplications associated with increased expression of ESRP1, which we validate in 12,000 tissue microarray tumors. Finally, we combined the patterns of molecular co-occurrence and risk-based subgroup information to deconvolve the molecular and clinical trajectories of prostate cancer from single patient samples.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Biomarcadores Tumorais / Regulação Neoplásica da Expressão Gênica / Metilação de DNA / Transcriptoma Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Biomarcadores Tumorais / Regulação Neoplásica da Expressão Gênica / Metilação de DNA / Transcriptoma Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article